



2024/9/25

產業類別	生技	
投資建議	中立	
收盤價	NT\$ 81.10	目標價
		NT\$

本次報告：法說會

### 交易資料

潛在報酬率 (%)	--
52 週還原收盤價區間 (NT\$)	70.30-114.00
市值 (NT\$ 百萬元)	22150
市值 (US\$ 百萬美元)	693
流通在外股數 (百萬股)	273.00
董監持股 (%)	22.97
外資持股 (%)	7.39
投信持股 (%)	0.08
融資使用率 (%)	10.44

### 財務資料

	2023
股東權益 (NT\$ 百萬元)	2,566
ROA (%)	-4.87
ROE (%)	-7.38
淨負債比率 (%)	34.1

### 公司簡介

中裕成立於 2007 年，為一專注於治療愛滋病藥品之研發公司，旗下產品線包括已上市之 Trogarzo 外，雙抗長效型針劑 TMB 365-380 預計年底至明年初公告 P2a 臨床數據，長效型 ADC 注射藥物 365+ 小分子藥，已完成體外概念驗證，目前進入設計優化階段。

主要客戶：

主要競爭對手：

陳奕均 fion.chen@sinozac.com

## 中裕 (4147 TT)

靜待 TMB 365-380 更詳細臨床數據結果


### 永豐觀點

雙抗愛滋病長效型藥物 TMB-365/380 將於年底至 1Q25 公布 P2a 臨床數據。

### 投資評價與建議


投資建議維持中立：雖中裕雙抗長效型愛滋病藥 TMB 365-380 將於年底至明年初公告 P2a 臨床試驗數據結果，惟考量後續商業價值或授權機會較高之時間點將落於臨床 P2b 即完整臨床二期結束後，故在還有一段時間需等待下，維持中立建議。

### 近八季營收及 YoY 趨勢圖



資料來源：CMoney；永豐投顧研究處整理 · Sep. 2024

### 近八季營業利益及毛利率趨勢圖



資料來源：CMoney；永豐投顧研究處整理 · Sep. 2024

## ✍ 營運現況與分析

**公司簡介：**中裕成立於 2007 年，為一專注於治療愛滋病藥品之研發公司，旗下產品線包括已上市之 Trogarzo 外，雙抗長效型針劑 TMB 365-380 預計年底至明年初公告 P2a 臨床數據，長效型 ADC 注射藥物 365+小分子藥，已完成體外概念驗證，目前進入設計優化階段。

**目前營收來自已上市藥品 Trogarzo 之銷售：**中裕目前營收來源為已上市愛滋病藥品 Trogarzo，1H24 年營收 3.26 億元(+85.2%YoY)，較去年增幅較大，主因銷售夥伴去年上半年仍處庫存消化階段所致，毛利率 38.7%，稅後虧損 0.44 億元，稅後 EPS-0.17 元，就此藥後續策略上，除美國市場外，中裕今年陸續與友華生技、AcedrA 及五洲製藥簽訂台灣、中東、北菲、港澳等地銷售行銷契約，然考量此藥目標市場為四五線病患、市場規模較小，預估中裕月營收將維持在 4-6 千萬元，另因公司竹北廠區除生產研發中藥品外，今年已有一客戶進行蛋白質藥 CDMO 業務，預計明年還會再增一到兩個客戶。

**雙抗愛滋病長效型藥物 TMB-365/380 將於年底至 1Q25 公布 P2-a 臨床數據：**愛滋病目前藥物使用方式九成仍以口服小分子藥為主，但因口服藥需每天服用，且副作用較大並產生藥物間交互作用情況下，易造成病人依從性差進而導致治療失敗，故開發長效型藥物為當前廠商開發趨勢所在，此從 GSK/ViiV 已上市長效性針劑 Cabenuva 上市僅三年市場銷值快速成長可得知，中裕開發之兩個月注射一次雙抗長效型藥 TMB-365/380 相較 Cabenuva，因屬全效型單株抗體組合，不需再搭配其他小分子藥物，較無副作用，注射上也較無疼痛感下，極具市場競爭力，以美國地區已接受愛滋病藥物治療病患 40-50 萬人，預計藥價 4-5 萬美金計算，目標市場產值達 160-250 億美金，就中裕 TMB-365/380 進度，公司已於八月完成 Phase 2a 最後一名病患最後一劑施打，加計八週後需要抽血檢測及四週的後續追蹤，預計年底至明年初將公布臨床試驗初步結果，倘若數據不錯，將於 2025 年啟動 Phase 2b，就授權規劃上，考量授權價值隨臨床階段往後而提高，故此藥授權時間預計最快也要待整體二期臨床結束後始會展開。

**財務預估：**預估中裕 2024 年營收 6.21 億元(+26.3%YoY)，毛利率 39.3%，稅後虧損 1.47 億元，稅後 EPS-0.58 元，2025 年營收 6.45 億元(+3.8%YoY)，毛利率 40.2%，稅後虧損 1.92 億元，稅後 EPS-0.76 元。

附表一：當年度損益表

單位：百萬元	24Q1	24Q2	24Q3F	24Q4F	2024F
營業收入	179	147	145	150	621
營業毛利	68	58	58	60	244
營業利益	-37	-41	-52	-52	-183
稅前淨利	-16	-28	-52	-52	-147
稅後純益	-16	-28	-52	-52	-147
稅後 EPS (元)	-0.06	-0.10	-0.19	-0.19	-0.58
營收 QoQ 成長率	13.10	-17.89	-0.68	3.45	--
營收 YoY 成長率	149.35	40.96	-7.64	-5.06	26.48
毛利率	38.11	39.43	40.00	40.00	39.29
營益率	-20.70	-28.07	-35.86	-34.67	-29.47
稅後純益率	-8.96	-18.74	-35.86	-34.67	-23.67

資料來源：CMoney；永豐投顧研究處整理，Sep. 2024

附表二：五個年度損益表

單位：百萬元	2021	2022	2023	2024F	2025F
營業收入	413	563	492	621	645
%變動率	-42.78	36.18	-12.65	26.22	3.86
營業毛利	84	216	225	244	259
毛利率 (%)	20.31	38.31	45.80	39.29	40.16
營業淨利	-486	-192	-166	-183	-186
稅前淨利	-471	-269	-195	-147	-192
%變動率	--	--	--	--	--
稅後純益	-471	-269	-195	-147	-192
%變動率	--	--	--	--	--
稅後 EPS * (元)	-1.87	-1.07	-0.77	-0.58	-0.76
市調 EPS * (元)	-0.76	-1.13	-0.70	-0.31	--
PER (x)	--	--	--	--	--
PBR (x)	6.96	7.54	8.00	5.43	5.72
每股淨值 * (元)	11.66	10.75	10.14	14.93	14.17
每股股利 (元)	0.00	0.00	0.00	--	--
殖利率 (%)	--	--	--	--	--

\* 以目前股本計算


資料來源：CMoney；永豐投顧研究處整理 · Sep. 2024

## 營運基本資料


### 同業比較

代號	公司	投資建議	目前股價	市值(億)	稅後 EPS		PE		PB	
					2023	2024	2023	2024	2023	2024


### 近三年單月營收狀況




### 近三年單季營收 VS 毛利率趨勢圖



### 負債比率 VS 存貨周轉天數



### 歷史 PB 圖



臺北	永豐證券投資顧問股份有限公司 臺北市忠孝西路一段 80 號 14 樓 電話：(886-2) 2361-0868	永豐金證券股份有限公司 臺北市重慶南路一段 2 號 17 樓 電話：(886-2) 2311-4345
香港	永豐金證券(亞洲)有限公司 香港銅鑼灣新寧道 1 號 7 樓 電話：(852) 2586-8288	
上海	永豐金證券(亞洲)有限公司上海代表處 中國上海市浦東新區世紀大道 1528 號陸家嘴基金大廈 1903A-2 室 電話：(86-21) 6228-8220	

#### 責任聲明

本報告內容僅供參考，客戶應審慎考量本身之需求與投資風險，本公司恕不負任何法律責任，亦不作任何保證。本報告中之內容或有取材於本公司認可之來源，但並不保證其真實性或完整性；報告中所有資訊或預估，變更時本公司將不作預告，若資料內容有未盡完善之處，恕不負責。此外，非經本公司同意，不得將本報告加以複製或轉載。

110 年金管投顧新字第 024 號

#### SinoPac 投資評等

B：Buy 買進：未來 12 個月該股票表現將優於大盤

N：Neutral 中立：未來 12 個月該股票表現將與大盤一致

S：Sell 賣出：未來 12 個月該股票表現將落後大盤

---

**Analyst Certification:**

For each company mentioned in this research report, the respective analyst(s) who cover the company certifies (certify) that all of the views expressed in this research report accurately reflect his (their) personal views about any and all of the subject issuer(s) or securities. The analyst(s) also certifies (certify) that no part of her (their) compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

**SinoPac Research Stock Rating System:**

**Buy:** We think the stock will outperform the broader market over the next 12 months.

**Neutral:** We think the stock will perform in line with the broader market over the next 12 months.

**Sell:** We think the stock will underperform the market over the next 12 months.

**Global Disclaimer:****Important Disclosures for U.S. Persons**

This research report was prepared by SinoPac Securities Corporation (SinoPac), a company authorized to engage in securities activities in Taiwan. SinoPac is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act").

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Auerbach Grayson & Company, 20 Wall West 55th Street, New York, NY 10019, a registered broker dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through SinoPac. Auerbach Grayson & Company accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of Auerbach Grayson & Company and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

**Ownership and Material Conflicts of Interest**

Auerbach Grayson & Company or its affiliates does not 'beneficially own,' as determined in accordance with Section 13(d) of the Exchange Act, 1% or more of any of the equity securities mentioned in the report. Auerbach Grayson & Company, its affiliates and/or their respective officers, directors or employees may have interests, or long or short positions, and may at any time make purchases or sales as a principal or agent of the securities referred to herein. Auerbach Grayson & Company is not aware of any material conflict of interest as of the date of this publication.

**Compensation and Investment Banking Activities**

Auerbach Grayson & Company or any affiliate has not managed or co-managed a public offering of securities for the subject company in the past 12 months, nor received compensation for investment banking services from the subject company in the past 12 months, neither does it or any affiliate expect to receive, or intends to seek compensation for investment banking services from the subject company in the next 3 months.

**Additional Disclosures**

This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither SinoPac nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report.

SinoPac may rely on information barriers, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of SinoPac.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by SinoPac with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of SinoPac and SinoPac accepts no liability whatsoever for the actions of third parties in this respect.